Evidence map›Paper›PMID 39527541›Full record

ArticlePloS one2024

Postoperative Karnofsky performance status prediction in patients with IDH wild-type glioblastoma: A multimodal approach integrating clinical and deep imaging features.

Tomoki Sasagasako, Akihiko Ueda, Yohei Mineharu, Yusuke Mochizuki, Souichiro Doi, Silsu Park, Yukinori Terada, Noritaka Sano, Masahiro Tanji, Yoshiki Arakawa and 1 more

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tomoki SasagasakoDepartment of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.ORCID 0000-0003-0157-8093
Akihiko UedaDepartment of Biomedical Data Intelligence, Kyoto University Graduate School of Medicine, Kyoto, Japan.ORCID 0000-0001-8139-9292
Yohei MineharuDepartment of Artificial Intelligence in Healthcare and Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.ORCID 0000-0002-6346-3999
Yusuke MochizukiKyoto University Faculty of Medicine, Kyoto, Japan.
Souichiro DoiKyoto University Faculty of Medicine, Kyoto, Japan.
Silsu ParkDepartment of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Yukinori TeradaDepartment of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Noritaka SanoDepartment of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.ORCID 0000-0002-8999-1976
Masahiro TanjiDepartment of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Yoshiki ArakawaDepartment of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Yasushi OkunoDepartment of Biomedical Data Intelligence, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeGlioblastoma is a highly aggressive brain tumor with limited survival that poses challenges in predicting patient outcomes. The Karnofsky Performance Status (KPS) score is a valuable tool for assessing patient functionality and contributes to the stratification of patients with poor prognoses. This study aimed to develop a 6-month postoperative KPS prediction model by combining clinical data with deep learning-based image features from pre- and postoperative MRI scans, offering enhanced personalized care for glioblastoma patients. MATERIALS AND

methodsUsing 1,476 MRI datasets from the Brain Tumor Segmentation Challenge 2020 public database, we pretrained two variational autoencoders (VAEs). Imaging features from the latent spaces of the VAEs were used for KPS prediction. Neural network-based KPS prediction models were developed to predict scores below 70 at 6 months postoperatively. In this retrospective single-center analysis, we incorporated clinical parameters and pre- and postoperative MRI images from 150 newly diagnosed IDH wild-type glioblastoma, divided into training (100 patients) and test (50 patients) sets. In training set, the performance of these models was evaluated using the area under the curve (AUC), calculated through fivefold cross-validation repeated 10 times. The final evaluation of the developed models assessed in the test set.

resultsAmong the 150 patients, 61 had 6-month postoperative KPS scores below 70 and 89 scored 70 or higher. We developed three models: a clinical-based model, an MRI-based model, and a multimodal model that incorporated both clinical parameters and MRI features. In the training set, the mean AUC was 0.785±0.051 for the multimodal model, which was significantly higher than the AUCs of the clinical-based model (0.716±0.059, P = 0.038) using only clinical parameters and the MRI-based model (0.651±0.028, P<0.001) using only MRI features. In the test set, the multimodal model achieved an AUC of 0.810, outperforming the clinical-based (0.670) and MRI-based (0.650) models.

conclusionThe integration of MRI features extracted from VAEs with clinical parameters in the multimodal model substantially enhanced KPS prediction performance. This approach has the potential to improve prognostic prediction, paving the way for more personalized and effective treatments for patients with glioblastoma.

Indexed as

Brain NeoplasmsDeep LearningGlioblastomaIsocitrate DehydrogenaseKarnofsky Performance StatusMagnetic Resonance ImagingAdultAgedFemaleHumansMaleMiddle AgedMultimodal ImagingPostoperative PeriodPrognosisRetrospective StudiesIsocitrate Dehydrogenase

Identifiers

PMID39527541
PMCPMC11554073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.